Dublin, Dec. 12, 2017 -- The "Growth Insights on the US Therapeutic Apheresis Market, Forecast to 2021" report has been added to Research and Markets' offering.
Product Diversification, Focus on Therapeutic Plasmapheresis and Pathogen-Reduced Platelets Will Be Key to Success
The study covers current and future market trends, drivers, challenges, and opportunities in US therapeutic apheresis market. It breaks down the market into hematology and oncology, neurology, rheumatology, and other therapeutic areas. Therapeutic apheresis has become an essential element of the blood and blood components industry value chain. Hospitals are the primary users of apheresis equipment and solutions; other users include blood banks and dialysis centers. End users include therapeutic apheresis nurses, referring physicians, hematologists, oncologists, rheumatologists, neurologists, nephrologists, cardiologists, and lipidologists.
The study covers standard plasmapheresis or plasma exchange, extracorporeal immunoadsorption, plateletpheresis, red cell exchange, leukapheresis, and lipidpheresis. The two broad product categories are devices and disposables.
The study discusses key trends that are expected to impact the market, including more applications across different therapeutics segments and diversification aimed at long-term growth. The industry is also witnessing a shift as the adoption of apheresis procedures, with more growth possibilities in autoimmune, renal and rare disease therapeutic areas.
The study examines the 2016 market size and presents a forecast through 2021, as well as the current market share of therapeutic areas. It offers a regulatory overview and a look at reimbursement and pricing trends. It also discusses the competitive landscape and the key market players in the industry.
Key Topics Covered:
1. Executive Summary
- Key Findings
2. Market Overview
- Market Definition
- Market Scope and Segmentation
- Key Questions This Study Will Answer
- Value Chain Analysis
3. Market Trends
- Market Dynamics
- Market Impact of Top Trends
- Regulatory Overview
- Reimbursement Trends
4. Drivers and Restraints
- Market Drivers
- Market Restraints
5. Forecast and Trends
- Forecast Assumptions
- Market Forecast Scenarios
- Forecast by Therapeutic Category
- Pricing Trends
6. Competitive Landscape
- Competitive Environment
- Key Vendors to Watch
- Key Service Providers to Watch
7. Growth Opportunities and Companies to Action
- Growth Opportunity 1-Growing Application and Scope of Therapeutic Plasmapheresis
- Growth Opportunity 2-Increasing Focus on Diversifying Product Applications
- Growth Opportunity 3-Pathogen-Reduced Platelets and Plasma
- Strategic Imperatives
8. ECP Treatments-Market Insights
- ECP Treatments-Market Insights
9. Appendix
For more information about this report visit https://www.researchandmarkets.com/research/9mv83c/united_states?w=12
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Blood Banking


Washington Post Publisher Will Lewis Steps Down After Layoffs
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 



